{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:02:11Z","timestamp":1787497331722,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"DOI":"10.7759\/cureus.100108","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:07:07Z","timestamp":1766747227000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Empagliflozin-Linagliptin Fixed-Dose Combination on Chronic Kidney Disease Outcomes in Patients With Type 2 Diabetes in a Real-World Setting"],"prefix":"10.7759","author":[{"given":"Debmalya","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyabrata","family":"RoyChaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-017-0036-3","article-title":"Confessions of a thin-fat Indian","volume":"72","author":"Yajnik CS","year":"2018","unstructured":"Yajnik CS. Confessions of a thin-fat Indian. Eur J Clin Nutr. 2018, 72:469-73. 10.1038\/s41430-017-0036-3","journal-title":"Eur J Clin Nutr"},{"key":"ref2","article-title":"Stratifying renal risk and retinal involvement in South Indian type 2 diabetic patients: using the KDIGO classification","volume":"5","author":"Rani A","year":"2017","unstructured":"Rani A, Satyavani K, Viswanathan V. Stratifying renal risk and retinal involvement in South Indian type 2 diabetic patients: using the KDIGO classification. Int J DiabetolVasc Dis Res. 2017, 5:196-201.","journal-title":"Int J DiabetolVasc Dis Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004218","article-title":"Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS Trial","volume":"12","author":"Singh K","year":"2024","unstructured":"Singh K, Kondal D, Jagannathan R, et al.. Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS Trial. BMJ Open Diabetes Res Care. 2024, 12:e004218. 10.1136\/bmjdrc-2024-004218","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas S","year":"2017","unstructured":"Zoungas S, Arima H, Gerstein HC, et al.. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes and Endocrinology. 2017, 5:431-7.","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm - 2023 Update","volume":"29","author":"Samson SL","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, et al.. American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm - 2023 Update. Endocr Pract. 2023, 29:305-40. 10.1016\/j.eprac.2023.02.001","journal-title":"Endocr Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes. An individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","unstructured":"Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes. An individual-participant data meta-analysis. JAMA. 2023, 330:1266-77. 10.1001\/jama.2023.17002","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-SREV","article-title":"Summary of revisions: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Summary of revisions: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S6-S13. 10.2337\/dc25-SREV","journal-title":"Diabetes Care"},{"key":"ref10","article-title":"Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management","author":"Del Prato S","year":"2007","unstructured":"Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract Suppl. 2007, 47-57.","journal-title":"Int J Clin Pract Suppl"},{"key":"ref11","unstructured":"Boehringer Ingelheim. Glyxambi prescribing information. (2024). Accessed. June 6, 2025: https:\/\/pro.boehringer-ingelheim.com\/in\/products\/glyxambi\/prescribing-information."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13130","article-title":"Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors","volume":"20","author":"Fadini GP","year":"2018","unstructured":"Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018, 20:740-4. 10.1111\/dom.13130","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100783","article-title":"Empagliflozin and rapid kidney function decline incidence in type 2 diabetes: an exploratory analysis from the EMPA-REG OUTCOME trial","volume":"6","author":"Hadjadj S","year":"2024","unstructured":"Hadjadj S, Cooper ME, Steubl D, et al.. Empagliflozin and rapid kidney function decline incidence in type 2 diabetes: an exploratory analysis from the EMPA-REG OUTCOME trial. Kidney Med. 2024, 6:100783. 10.1016\/j.xkme.2023.100783","journal-title":"Kidney Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"The Nuffield Department of Population Health Renal Studies Group","year":"2022","unstructured":"The Nuffield Department of Population Health Renal Studies Group, The SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022, 400:1788-801. 10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. A meta-analysis","volume":"6","author":"McGuire DK","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. A meta-analysis. JAMA Cardiol. 2021, 6:148-58. 10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2165\/11630900-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of linagliptin","volume":"51","author":"Graefe-Mody U","year":"2012","unstructured":"Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012, 51:411-27. 10.2165\/11630900-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA. 2019, 321:69-79. 10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0279","article-title":"Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial","volume":"43","author":"Perkovic V","year":"2020","unstructured":"Perkovic V, Toto R, Cooper ME, et al.. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care. 2020, 43:1803-12. 10.2337\/dc20-0279","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker LA","year":"2023","unstructured":"Inker LA, Collier W, Greene T, et al.. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023, 29:1867-76. 10.1038\/s41591-023-02418-0","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus BJ","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, et al.. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021, 99:750-62. 10.1016\/j.kint.2020.10.031","journal-title":"Kidney Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002743","article-title":"The RIFLE criteria and mortality in acute kidney injury: a systematic review","volume":"73","author":"Ricci Z","year":"2008","unstructured":"Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008, 73:538-46. 10.1038\/sj.ki.5002743","journal-title":"Kidney Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1121","article-title":"The kidney in heart failure: the role of venous congestion","volume":"18","author":"Tamayo-Gutierrez A","year":"2022","unstructured":"Tamayo-Gutierrez A, Ibrahim HN. The kidney in heart failure: the role of venous congestion. Methodist Debakey Cardiovasc J. 2022, 18:4-10. 10.14797\/mdcvj.1121","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref24","article-title":"Diuretics for people with chronic kidney disease","volume":"2017","author":"Shah PB","year":"2017","unstructured":"Shah PB, Soundararajan P, Sathiyasekaran BW, Hegde SC. Diuretics for people with chronic kidney disease. Cochrane Database Syst Rev. 2017, 2017:CD011339.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0000852020","article-title":"Anemia and incident end-stage kidney disease","volume":"1","author":"Saraf SL","year":"2020","unstructured":"Saraf SL, Hsu JY, Ricardo AC, et al.. Anemia and incident end-stage kidney disease. Kidney360. 2020, 1:623-30. 10.34067\/kid.0000852020","journal-title":"Kidney360"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14963","article-title":"Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes","volume":"25","author":"Packer M","year":"2023","unstructured":"Packer M. Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. Diabetes Obes Metab. 2023, 25:1143-6. 10.1111\/dom.14963","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106243","article-title":"The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis","volume":"180","author":"Theofilis P","year":"2022","unstructured":"Theofilis P, Antonopoulos AS, Katsimichas T, et al.. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022, 180:106243. 10.1016\/j.phrs.2022.106243","journal-title":"Pharmacol Res"},{"key":"ref28","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink HJL","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, et al.. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019, 7:128-39.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4948-4","article-title":"The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study","volume":"62","author":"Oshima M","year":"2019","unstructured":"Oshima M, Jun M, Ohkuma T, et al.. The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia. 2019, 62:1988-97. 10.1007\/s00125-019-4948-4","journal-title":"Diabetologia"},{"key":"ref30","article-title":"Single-pill combination of empagliflozin and linagliptin in real world Indian type 2 diabetes patient (GRID)","volume":"68","author":"Kovil R","year":"2020","unstructured":"Kovil R, Saboo B, Shah K, Padhye D, Chudasama D, Raj V, Shaikh N. Single-pill combination of empagliflozin and linagliptin in real world Indian type 2 diabetes patient (GRID). J Assoc Physicians India. 2020, 68:53-5.","journal-title":"J Assoc Physicians India"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.2337\/db20-2206-PUB","article-title":"2206-PUB: efficacy of fixed-dose combination of empagliflozin and linagliptin in addition to the ongoing treatment in type 2 diabetes: real-world observational study","volume":"69","author":"Gupta A","year":"2020","unstructured":"Gupta A, Khalse M, Bhargava A. 2206-PUB: efficacy of fixed-dose combination of empagliflozin and linagliptin in addition to the ongoing treatment in type 2 diabetes: real-world observational study. Diabetes. 2020, 69:2206-PUB.","journal-title":"Diabetes"},{"key":"ref32","article-title":"A retrospective analysis of fixed combination of empagliflozin and linagliptin in addition to the existing treatment for its clinical effectiveness in adults with type 2 diabetes: a real-world clinical experience","volume":"69","author":"Gupta A","year":"2021","unstructured":"Gupta A, Malhotra P, Jamwal V, Khalse M. A retrospective analysis of fixed combination of empagliflozin and linagliptin in addition to the existing treatment for its clinical effectiveness in adults with type 2 diabetes: a real-world clinical experience. J Assoc Physicians India. 2021, 69:11-2.","journal-title":"J Assoc Physicians India"},{"key":"ref33","article-title":"Effectiveness and safety of a single-pill combination of empagliflozin\/linagliptin in individuals with uncontrolled type 2 diabetes with CKD: a single-centre outpatient clinic real-world experience","volume":"48","author":"Mahajan S","year":"2024","unstructured":"Mahajan S. Effectiveness and safety of a single-pill combination of empagliflozin\/linagliptin in individuals with uncontrolled type 2 diabetes with CKD: a single-centre outpatient clinic real-world experience. CJD. 2024, 48:S20.","journal-title":"CJD"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/423115-effectiveness-of-empagliflozin-linagliptin-fixed-dose-combination-on-chronic-kidney-disease-outcomes-in-patients-with-type-2-diabetes-in-a-real-world-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:07:09Z","timestamp":1766747229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/423115-effectiveness-of-empagliflozin-linagliptin-fixed-dose-combination-on-chronic-kidney-disease-outcomes-in-patients-with-type-2-diabetes-in-a-real-world-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.100108","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}